Evaluation of Copper, Zinc, Cu/Zn, and VEGF in Patients with AML in Iran

Zohreh  Sanaat; M Nouri; B Hajipour; R Dolatkhah; I Asvadi; J Vaez; J Eivazi; A Nikanfar; A Esfahani; SH Chavoshi; H Biorani

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

Outlines

Abstract
Copyright

Evaluation of Copper, Zinc, Cu/Zn, and VEGF in Patients with AML in Iran

Author(s):

Zohreh Sanaat^1,*,

M Nouri²,

B Hajipour¹,

R Dolatkhah¹,

I Asvadi¹,

J Vaez¹,

J Eivazi¹,

A Nikanfar¹,

A Esfahani¹,

SH Chavoshi¹,

H Biorani³

1Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2Department of Biochemistry, Tabriz University of Medical Sciences, Tabriz, Iran

3Department of Mathematic, Tabriz University, Tabriz, Iran

International Journal of Cancer Management:Vol. 4, issue 4; e80749

Published online:Dec 30, 2011

Article type:Brief Report

Received:Feb 18, 2011

Accepted:Jul 12, 2011

How to Cite:Zohreh SanaatM NouriB HajipourR DolatkhahI AsvadiJ VaezJ EivaziA NikanfarA EsfahaniSH ChavoshiH Bioraniet al.Evaluation of Copper, Zinc, Cu/Zn, and VEGF in Patients with AML in Iran.Int J Cancer Manag.4(4):e80749.

Abstract

Background: Copper and zinc are the elements with numerous physiological activities. Copper (Cu) has an important role in angiogenesis and acts by increasing Vascular Endothelial Growth Factor (VEGF). Serum levels of copper will be increased in cancer incidence, progression and recurrence. The aim of this study was to measure blood levels of copper, zinc, and the ratio of Cu /Zn, as well as VEGF levels before and after treatment of acute myeloid leukemia.

Methods: Thirty patients who were recently diagnosed with Acute Myeloblastic Leukemia (AML) in Shahid Ghazi Tabatabai oncology hospital enrolled in this clinical trial. On the first day, blood samples were taken for copper, zinc, and VEGF assay and flowcytometry. Treatment protocol was (7×3) regimen. Blood samples were collected for evaluation of copper, zinc, and VEGF. They were sent to Biochemistry Laboratory in medicine faculty for analysis.

Results: Amongst 30 AML patients, 14 (46.7%) were female and 16 (53.3%) were male. Patients of various ages ranged from 16 to 53 years, with a median age of 9.1±9.35 years. The mean serum level of copper, zinc, and mean Cu/Zn ratio before and after treatment showed significant difference (p<0.05) There was also significant difference between the mean VEGF level before and after treatment (p<0.05).

Conclusion: This study reveals that there is no significant relationship between copper, zinc serum levels, their ratio, and VEGF in AML patients. We hypothesize that increased serum copper is associated with increase of VEGF levels which can indicate the impact of copper in malignancies including AML.

Keywords

Copper

Zinc

Vascular Endothelial Growth Factor A

Fulltext

The Full text is available in PDF.

comments